Next Edge Bio-Tech Plus Fund: Investment Manager


Eden’s experience includes over two decades of portfolio and hedge fund money management, Options Strategist, Derivatives & Biotech analyst and portfolio manager. He has managed and traded an options book spanning 250+ securities globally and 4 commodities, with open interest of 500,000 contracts in addition to 14 Covered Call ETFs (over $0.5 Billion AUM) in Canada, US & Australia employing his dynamic options writing discipline at Horizons Exchange Traded Funds.

Eden possesses a top quartile 5-year, 5-Star growth fund Portfolio Manager track record on over billion in assets across 4 mandates at RBC Global Asset Management. In addition, Eden has delivered a +26% compounded annual return across a biotechnology mandate between 1995-2003. He also has extensive institutional hedging experience through major crises, and the structuring of Notes to create specific payoff profiles.

Eden is a regular guest speaking about the Bio-Tech industry on Bloomberg TV and BNN as well as an author and contributor to many industry papers and press articles. Eden holds a B.Sc. in Molecular Genetics from the University of Toronto.


Michaels 25 year’s options trading experience provides investors with unique exposure to alternative yield solutions.

Michael Bird joins Next Edge Capital with over twenty five years of options and derivate trading experience. He was previously head of the equity derivative group at Desjardin Securities. Other previous experience includes working as a senior trader in the equity derivative group at RBC-DS, as well as proprietary trading at CIBC Wood Gundy and McLeod Young Weir (BNS).

Michael has served on the TSE Derivative Markets Committee and is a Director and Board Member of Intrinsyc Technologies Corporation (TSX: ITC).